This was posted on another board: I. CEO said that 3

New Post Public Reply Private Reply Replies (1) Message Board
DonDonDon
1,862
This was posted on another board:

I. CEO said that 3 papers are being printed about anecdotal (pre-trial)
(A) Dr. Harish Seethamraju - 11 patients
(B) Dr. Otto Yang - 29 patients
(C) Dr. Nicholas Agresti - 4 patients (agresti)

II. Shorting (Andrew Left, Citron)
- FINRA/SEC probably will be looking into it
- 51 million shares trading

III. Story of how it got started at COVID
- CYDY heard that CCR-5 was related to COVID, so asked for Phase II from FDA. But FDA said no because no data from lab or animals on COVID.
- But then Dr. Seethamraju applied

IV. Un-blinding
- 86 patients in mild/moderate June 17 - patient enrolled. July 1 done (14 days).
- Cannot unblind immediately. Need every hospital to sign that their data is correct, etc.
- We will have results in July, don't know how quickly. Hesitant to say projection

V. Uplisting
NASDAQ
- have price to qualify
- have potential to raise money for NASDAQ
- does not want to raise money and dilute
- double digits is not enough
- every banker told me i'm stupid
- We're going to uplist on NASDAQ but try to avoid raising money
- Should have something to talk about within a few weeks

VI. Mike Mulholland up his sleeve
- shortcut to uplisting (of allowing to join NASDAQ without funding requirement)
- waiting to hear back if they will allow

VII. Talking with Big Pharma
- Every license/buyout discussion requires CDA (confidentiality agreement)
- We have been talking to Big Pharma & Big Media
- Will hear when results come out
- Will be multiple opportunities

VIII. Trials
- Capacity: 1.2 million vials this year and 10 million vials next year
- But if we have what we think we have, and we get approval, we'll have all the help we need from the government and other funding situations that are not dilutive.

VIII. Foreign Countries
- Our CRO (?) Amorex is very efficient
- United Kingdom: Took a while for them to get clearance, but trial should start soon.
- Mexico: we are very responsive--took 2 weeks for country to get memorandum of understanding. CYDY got back to them within a couple of days
- Brazil: also starting at some point soon, but they are dragging a bit.

IX. Q. Why is it taking so long for Leronlimab to get traction (vs. Remdesevir)
- Only Dr. Seethamraju requested it for EIND.
- Also, CCR-5 is a relatively new focus of study
- Initially, FDA didn't think it was promising
- But Gilead and Remdesevir were known, so FDA supported and got 50 sites up and running
- But as time passed, FDA came on board.

X. India and Pakistan?
- They have not reached out.
- CYDY doesn't reach out to countries but our hands are full; but we are very responsive to requests.
- So countries need to have their own health departments contact CYDY (here's my email)
- Interviewer offers to connect CYDY with these countries

XI. Pricing
- We will match/beat Remdesevir
- There are wealthy people who want to fund production for other countries, and we are happy to work with them and make a bit less in other countries.

XII. Contra-indications
- Have found zero drug-drug interactions
- Dr. Paul Madden (inventor) --> couldn't even kill a rat with it if we tried.
- Helps tremendously with MS (?)
- Animal studies with NASH have been amazing

XIII. Approval?
- How possible/likely is approval straight after Phase II?
- The issue is if there is "unmet medical need" can get quicker approval.
- Don't know what FDA will say..

XIV. Uninsured patients?
- Can they get the drug?
- presumably hospitals will give it out,

XV. Other uses of Leronlimab
- Dr. Lalezari (senior) has been at Einstein for 60 years
* wants to do trial immediately at Montefiore for Alzheimers
- NASH trial -- get started
- GBHT (?) - going on
- Cancer -- 23 difference cancers
- MS --> told Amorex to go forward
- HIV ongoing
- 10 trials this year (4 already in process, 6 more to go)

XVI. Dr. Patterson's Research
- The data from those labs belongs to Cydy
- But we like to let the doctors publish on their own ( Seethamraju, Yang, Agresti)
- Patterson has been great
- We've been getting leaders in each field
- Q: Patterson's paper? A: Labwork from IncellDX (?) re: CD-10, CD-12 (?)

XVII. Severe/Critical Trial Update
- Sitting at 127 patients, so no interim on 51 patients
- Being careful not to make any mistakes
- Hope to have data of CD-10 and CD-12 at same time

XVIII. Breast Cancer patients?
- 13 patients have (tumor?) at 0
- basket trial (?)

XIX. Comment -- So much appreciation for your work and your wife's contribution to the company.

XX. Surprise Question: What is the secret of leadership (one or two things) that you have learned and would like to share?
- I like to learn myself
- When I look at project and entrepreneur, must look at things in two ways: (a) analyze situation, get acquainted with every variable (monother

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 47

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 91

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 61

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 62

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 133

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 113

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 77

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading

Top 5 Most Recently Viewed Articles

InsCorp, Inc. Experiences Significant Growth Impact in 2025

Updated Category News Views 229

InsCorp, Inc. Sees Improved Financial Metrics in 2025 InsCorp, Inc. (OTCQX: IBTN) has announced results for the second quarter of 2025, demonstrating a noticeable upward trend in earnings per share (EPS) at $0.73, an increase from $0.57 in the prior quarter and $0.63 over the same period last year. Jim Rieniets, the President and CEO of INSBANK, expressed optimism about...

Continue Reading
Revance Celebrates National Sunscreen Day with Times Square Billboard

Updated Category News Views 223

Revance Celebrates National Sunscreen Day with a Bold Message Revance is thrilled to commemorate National Sunscreen Day with a vibrant digital billboard in Times Square. This event not only marks a celebration of Blue Lizard® Australian Sunscreen but also highlights the importance of sun safety as the summer season approaches. Blue Lizard is recognized as the leading...

Continue Reading
Exploring Noah Holdings' Strategic Vision for Global Growth

Updated Category News Views 523

Noah's Global Expansion and Innovative Services Noah Holdings has actively pushed the envelope in providing innovative financial services tailored to meet the diverse wealth management requirements of its clients. This year marks a significant chapter in their journey toward international expansion, where they are introducing groundbreaking solutions along with targeted...

Continue Reading
Streamline Your Taxes: Harness QuickBooks Reports Now

Updated Category News Views 21

QuickBooks: Not Just for Bookkeeping Anymore Taxes can be a pain, but if you're rocking QuickBooks, there's a silver lining. Karen Eberhart Metcalfe, the accounting whiz from Bolingbrook, IL, assures us that this tool isn't merely for ticking boxes in bookkeeping; it's your ace for navigating tax season with less sweat and more precision. When you’ve got those reports...

Continue Reading
Vistra's Options Trading Insights: What Big Investors Indicate

Updated Category News Views 177

Understanding Vistra's Options Trading Landscape Investors are closely observing the options trading activity for Vistra (NYSE: VST) as it indicates a notable bearish sentiment among significant traders. Retail traders would benefit from being aware of these trends. Current Market Sentiment Recent data revealed on options trading history highlights that a recognizable...

Continue Reading